A small study shows artificial intelligence can pick out individuals with coronavirus infections, but ophthalmologists and AI experts say the approach is far from proven to be capable of distinguishing infections with SARS-CoV-2 from other ills.
The changes, which affect the declarations authors have to sign and the peer-review process, have received a mixed response from the scientific community.
Eli Lilly reports a 72 percent reduction in hospitalization risk among patients who received its monoclonal antibody compared to those who received a placebo.
Researchers are trying to make sense of immune systems gone haywire and develop biomarkers to predict who will become the sickest from a coronavirus infection.
Student workers have cited a lack of transparency and a failure to implement rapid and widespread testing among their many concerns regarding the school’s response to the pandemic.
A randomized controlled trial on the use of convalescent plasma therapy to treat coronavirus ...
